Cargando…
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
Guidelines for the treatment of schizophrenia limit the use of antipsychotic agents to clinically-established maximum doses. This acknowledges both the absence of additional efficacy of dopamine D2 receptor antagonists above a receptor occupancy threshold, and the increases in side effects that can...
Autor principal: | Reynolds, Gavin P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436307/ https://www.ncbi.nlm.nih.gov/pubmed/34256637 http://dx.doi.org/10.1177/02698811211026456 |
Ejemplares similares
-
Rethinking bystander CPR for out-of-hospital cardiac arrest
por: Crane, Scott A, et al.
Publicado: (2008) -
Economics & ethics of the COVID-19 vaccine: How prepared are we?
por: Gupta, Indrani, et al.
Publicado: (2020) -
Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020) -
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
por: Seeman, P
Publicado: (2016) -
Could dopamine be a silent killer?
por: Azarov, Nick, et al.
Publicado: (2007)